BIODESIX, INC. Restricted Cash, Current
BIODESIX, INC. (BDSX) had Restricted Cash, Current of $100.00 thousand as of 2022-09-30, per its 10-Q filed 2022-11-03.
Discontinued › Balance Sheet › Assets
us-gaap:RestrictedCashCurrent · last filed 2022-11-03
- 2022-09-30: Restricted Cash, Current $100.00K.
- 2021-12-31: Restricted Cash, Current $100.00K.
| Period end | Restricted Cash, Current |
|---|---|
| 2022-09-30 | $100.00K 10-Q · filed 2022-11-03 |
| 2021-12-31 | $100.00K 10-Q · filed 2022-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |